ANNEXON, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ANNEXON, INC. (ANNX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$206.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-30
- ANNEXON, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$206.68M.
- ANNEXON, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$138.19M, a 202.95% decline from fiscal 2023.
- ANNEXON, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $134.23M, a 5.43% decline from fiscal 2022.
- ANNEXON, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $141.94M, a 8.92% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$206.68M 10-K · filed 2026-03-30 | |
| 2024-12-31 | -$138.19M 10-K · filed 2026-03-30 | $138.19M 10-K · filed 2025-03-03 |
| 2023-12-31 | $134.23M 10-K · filed 2025-03-03 | |
| 2022-12-31 | $141.94M 10-K · filed 2024-03-26 | |
| 2021-12-31 | $130.31M 10-K · filed 2023-03-06 | -$130.31M 10-K · filed 2022-03-01 |
| 2020-12-31 | -$63.41M 10-K · filed 2022-03-01 | |
| 2019-12-31 | -$36.97M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |